Pharvaris director sells 14,493 shares at $38.56

A Pharvaris N.V. director exercised options and sold 14,493 shares in a cashless, pre-planned 10b5-1 transaction.

Available on EDGAR 09/21/2026 - 03:17 PM EDT Accepted by SEC EDGAR 09/21/2026 - 03:16 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) director Robert Glassman reported an option exercise and same-day sale involving 14,493 shares on September 17, 2026. He exercised stock options to acquire 14,493 shares of Common Stock at $18.14 per share and then sold 14,493 shares at a weighted average price of $38.5574 per share in a cashless exercise transaction. These transactions were carried out as a scheduled exercise and sale under a Rule 10b5-1 trading plan.

Insider Trade Summary

Exercise and Sale: 14,493 shares ($296K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Glassman Robert

Role Director

Sold 14,493 shs ($559K)

Approx. gross sale proceeds $559K

Approx. exercise cost $263K

Approx. pre-tax spread $296K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	14,493	$0.00	$0.00
Exercise	Common Stock F1	14,493	$18.14	$263K
Sale	Common Stock F1, F2	14,493	$38.5574	$559K

Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 10,500 shares (Direct)

Footnotes (3)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Options exercised: 14,493 shares Option exercise price: $18.14 per share Shares sold: 14,493 shares +3 more

6 metrics

Options exercised 14,493 shares Stock options exercised by director on September 17, 2026

Option exercise price $18.14 per share Exercise price for 14,493 stock options

Shares sold 14,493 shares Common Stock sold on September 17, 2026

Weighted average sale price $38.5574 per share Average for multiple sale transactions on September 17, 2026

Sale price range $38.26–$38.89 per share Price range of individual sales on September 17, 2026

Option expiration date April 1, 2032 Expiration of the exercised stock option

Key Terms

Rule 10b5-1 trading plan, cashless exercise transaction, weighted average sale price

3 terms

Rule 10b5-1 trading plan regulatory

"This is a scheduled exercise and sale from 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise transaction financial

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharvaris N.V. (PHVS) director Robert Glassman report?

He reported exercising options for 14,493 shares of Pharvaris N.V. Common Stock at $18.14 per share and selling 14,493 shares on September 17, 2026 as part of a cashless exercise transaction.

At what prices were the Pharvaris (PHVS) shares sold in this Form 4 filing?

The filing states a weighted average sale price of $38.5574 per share for the 14,493 shares sold. Individual sale prices in the multiple transactions that day ranged from $38.26 to $38.89 per share.

Were the Pharvaris (PHVS) insider transactions made under a Rule 10b5-1 plan?

Yes. A footnote explains that this was a scheduled exercise and sale under a Rule 10b5-1 trading plan, indicating the transactions were pre-arranged rather than opportunistic.

What type of derivative security did the Pharvaris (PHVS) director exercise?

He exercised a stock option (right to buy) covering 14,493 shares of Pharvaris N.V. Common Stock with an exercise price of $18.14 per share and an expiration date of April 1, 2032.

How did the Pharvaris (PHVS) stock option held by the director vest?

A footnote states that 25% of the option vested on April 1, 2023, with the remaining shares vesting in 1/48 monthly installments thereafter, describing a standard multi-year vesting schedule.

Was the Pharvaris (PHVS) insider sale a traditional sale or a cashless exercise?

The filing describes the sale as being made in connection with the exercise of stock options in a cashless exercise transaction, meaning the sale of shares funded the option exercise costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glassman Robert

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		M(1)		14,493	A	$18.14	24,993	D
Common Stock	09/17/2026		S(1)		14,493	D	$38.5574(2)	10,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.14	09/17/2026		M			14,493	(3)	04/01/2032	Common Stock	14,493	$0	0	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Robert Glassman	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)